Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Drugs Made In America Acquisition (DMAA) Income towards Parent Company (2025)

Drugs Made In America Acquisition filings provide 1 years of Income towards Parent Company readings, the most recent being $212958.0 for Q4 2025.

  • Quarterly Income towards Parent Company changed N/A to $212958.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $5.9 million for FY2025, 2222.83% up from the prior year.
  • Income towards Parent Company hit $212958.0 in Q4 2025 for Drugs Made In America Acquisition, down from $2.2 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $2.3 million in Q2 2025 and bottomed at $212958.0 in Q4 2025.